Skip to content
Search

Latest Stories

Type 2 Diabetes Path to Remission Programme to be rolled out across England

Type 2 Diabetes Path to Remission Programme to be rolled out across England

Over 1,150 people with type 2 diabetes and obesity or overweight in the West Midlands have benefited from this programme

NHS England is expanding the Type 2 Diabetes Path to Remission Programme across the country from April 2024, following the successful pilot launch in the Midlands.


A joint initiative between NHSE and Diabetes UK, the programme offers a low calorie, total diet replacement treatment for individuals who are living with type 2 diabetes and obesity or overweight.

More than 1,150 patients in the West Midlands have joined the programme and benefited from it since its introduction in 2020 until February 2024.

Previously known as the NHS Low Calorie Diet Programme, this evidence-based intervention is aimed at reversing diabetes and maintaining weight loss in the long term.

“This is such a great chance for people to take control of their health and to put their type 2 diabetes into remission,” said Professor Vinod Patel, West Midlands Clinical Lead for NHS England (Midlands) for Diabetes.

Peter Shorrick, head of Midlands and East at Diabetes UK, explained that achieving remission can help reduce the risk of developing serious problems with the eyes, feet, or heart in many patients with type 2 diabetes, while also providing hope for a medication-free future.

“People in remission say it’s life changing and we funded research that shows that this programme works.

“Our aim is to support people to go on the Path to Remission Programme and achieve results safely, complementing it with our advice on a range of issues from maintaining a healthy diet, to exercise, mental health and the importance of peer-to-peer support to provide a holistic approach,” he added.

This programme is based on research that found a 3-month specially formulated ‘soup and shake’ diet, coupled with healthy lifestyle support, helped people living with type 2 diabetes and obesity or overweight to lose over 10kg (1st  5lbs) in weight, improve their blood glucose levels, reduce diabetes-related medication and achieve remission of type 2 diabetes in almost half of the participants.

People aged 18 – 65 years who have been diagnosed with type 2 diabetes within the last six years, and have a BMI over 27 kg/m2 (for individuals from White ethnic groups) or over 25 kg/m2 (for individuals from Black, Asian and other ethnic groups) are eligible to participate in the NHS Type 2 Diabetes Path to Remission Programme.

James from Birmingham has lost 95kg (54 per cent of his body weight) since starting the programme in 2021.

“I now weigh 82kg. With a Hb1Ac (average blood glucose) of 29, my diabetes is in remission and my GP has advised me that I don’t need any diabetes treatment which is fantastic,” James said.

He was referred to the programme by a nurse practitioner from his GP surgery due to difficulties tolerating his medications. At that time, his weight was 177kg (27st 8 lbs).

More For You

Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less